Sangamo Therapeutics Inc.

NASDAQ: SGMO · Real-Time Price · USD
0.58
0.04 (7.41%)
At close: Aug 15, 2025, 3:59 PM
0.58
1.19%
After-hours: Aug 15, 2025, 06:34 PM EDT

Sangamo Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
57.8M 176.23M 111.3M 110.7M
Cost of Revenue
9.36M 22.19M 12.11M 9.44M
Gross Profit
57.8M 154.04M 99.19M 101.26M
Operating Income
-103.97M -274M -201.28M -183.34M
Interest Income
5.86M 11.1M 9.43M 5.35M
Pretax Income
-98.11M -262.9M -191.85M -177.99M
Net Income
-97.94M -257.83M -192.28M -178.3M
Selling & General & Admin
44.73M 61.17M 62.68M 63.22M
Research & Development
111.52M 234.06M 249.9M 230.82M
Other Expenses
5.52M -66.54M -12.11M -9.44M
Operating Expenses
161.77M 228.68M 300.47M 284.6M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
156.93M 450.24M 312.58M 294.04M
Income Tax Expense
-167K -5.07M 429K 306K
Shares Outstanding (Basic)
201.7M 174.44M 154.34M 144.57M
Shares Outstanding (Diluted)
201.7M 174.44M 154.34M 144.57M
EPS (Basic)
-0.49 -1.48 -1.25 -1.23
EPS (Diluted)
-0.49 -1.48 -1.25 -1.23
EBITDA
-89.09M -240.71M -189.17M -173.9M
EBIT
-98.45M -102.49M -201.28M -183.34M
Depreciation & Amortization
9.36M 22.19M 12.11M 9.44M